Overview of Efalizumab Placebo- controlled Phase III Trials

Efalizumab is a humanized IgG monoclonal antibody directed against the alpha chain of LFA-1 (CD11a) expressed on the surface of T cells.11 Efalizumab blocks the interaction between LFA-1 and ICAM-1 on APCs, vascular endothelial cells, and cells in the dermis and epidermis.

Related Videos
Related Content

Highlights from AAD 2023

March 23rd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

New Technology Could Allow Us to Rethink Alopecia Scores

March 23rd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Pregnant Women with Skin Conditions May Require Dermatologic Intervention

March 23rd 2023

Frontline Forum Part 3: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 23rd 2023

Highlights from AAD 2023

March 23rd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

New Technology Could Allow Us to Rethink Alopecia Scores

March 23rd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Pregnant Women with Skin Conditions May Require Dermatologic Intervention

March 23rd 2023

Frontline Forum Part 3: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 23rd 2023

Highlights from AAD 2023

March 23rd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

New Technology Could Allow Us to Rethink Alopecia Scores

March 23rd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Pregnant Women with Skin Conditions May Require Dermatologic Intervention

March 23rd 2023

Frontline Forum Part 3: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 23rd 2023
© 2023 MJH Life Sciences

All rights reserved.